AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ECO ANIMAL HEALTH GROUP PLC

Investor Presentation Sep 5, 2022

7612_rns_2022-09-05_2496bceb-6bb9-428b-b918-7d911b1d0132.html

Investor Presentation

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 3011Y

Eco Animal Health Group PLC

05 September 2022

ECO Animal Health Group plc

(''ECO" or "the Group")

(AIM: EAH)

Investor Presentation covering Full Year Results

ECO Animal Health Group plc ("ECO" or "the Group"), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that David Hallas, CEO, and Christopher Wilks, CFO, will be conducting a live presentation covering the Group's Full Year Results for the period ended 31 March 2022.

The online presentation will take place on Wednesday 7 September at 10.00am UK time. This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end of it.

To register for the event, please click here

A video recording of the presentation will be available shortly afterwards here

Contacts:

ECO Animal Health Group plc

David Hallas (Chief Executive)

Christopher Wilks (Finance Director)
020 8447 8899
IFC Advisory

Graham Herring

Zach Cohen
020 3934 6630
Singer Capital Markets (Nominated Adviser & Joint Broker)

Mark Taylor

George Tzimas
020 7496 3000
Investec (Joint Broker)

Gary Clarence

Brough Ransom

Carlo Spingardi

Peel Hunt LLP (Joint Broker)

Dr Christopher Golden

James Steel
020 7597 5970

020 7418 8900
Equity Development

Hannah Crowe

Matt Evans
020 7065 2692

About ECO Animal Health

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEAFNSESXAEFA

Talk to a Data Expert

Have a question? We'll get back to you promptly.